Can You Reverse Aging? A New Competition Tests Biological Age Clocks in Real Time

A startup-led competition called Younger is enrolling approximately 500 participants over six months to measure whether they can reduce their biological age through various health interventions, with results tracked on a public leaderboard. Biological age clocks attempt to measure aging through chemical markers on DNA, blood proteins, lipids, and other biomarkers, but scientists remain uncertain whether individual clocks accurately predict personal aging rates or lifespan. The initiative aims to generate data that could improve understanding of these aging measurement tools and their potential for predicting diseases like Alzheimer's.
The competition leverages multiple measurement approaches to assess aging across different biological systems. Participants submit blood samples for epigenetic analysis, complete cognitive assessments for brain age evaluation, provide physical measurements like grip strength, and submit facial photographs for age estimation. This multi-method approach reflects a broader strategy used by longevity clinics to address gaps in individual aging clock accuracy.
Scientists acknowledge significant uncertainty about what different biological age clocks actually measure and whether they reliably predict individual lifespan or disease risk. The Younger competition aims to generate large-scale data that could clarify which clocks capture meaningful aspects of aging and improve their predictive value for conditions like Alzheimer's disease.
The initiative could influence how aging measurement tools are developed and validated, potentially affecting future clinical applications in preventive medicine. If the competition produces insights into biological clock reliability, it may inform treatment decisions for people seeking longevity interventions. However, widespread adoption of unproven aging metrics could lead individuals to make health decisions based on uncertain data, highlighting the tension between scientific curiosity and premature clinical application of emerging biomarkers.